Oxford StemTech’s Post

Useful protocol for single cell #genomics #researchers. 👇 FixNCut preserves cellular integrity while allowing flexible sample handling, making it suitable for settings where immediate processing isn't possible. It supports single-cell assays like scRNA-seq and ATAC-seq and is compatible with various biological samples, ensuring RNA and DNA integrity. Additionally, FixNCut enables multi-center studies by facilitating sample fixation at collection points, reducing artifacts associated with stress or necrosis, and enhancing the reproducibility of single-cell analyses.

🔬 Are you looking to validate and characterize your cell lines with precision? At Neuroservices-Alliance, we specialize in advanced electrophysiological techniques like patch clamp and HD Multi Electrode Array to uncover cellular impairments and reveal how your drug candidates can make a difference. From wild-type cells to disease-modified lines, our expertise shines through—just like in our latest work with NGN2 iPSC-derived neurons, presented at SfN 2024. 🔹 Curious to see how we phenotyped these neurons? Check out the poster here: https://lnkd.in/gGGZANgM 🔗 Ready to elevate your research? Get in touch with us to discover how we can support your next breakthrough: https://lnkd.in/g8_xmiXw #CellPhenotyping #iPSC #neurons #stemcells #celllines #Electrophysiology #PatchClamp #DrugDevelopment #Research

We hope you found our recent seminars on live cell imaging in research intriguing. Curiosis recently concluded two successful events, focusing on these cutting-edge topics and showcasing our advanced Celloger® system. These seminars emphasized the critical role of real-time cell observation in deciphering disease mechanisms and pioneering new therapies. We look forward to your continued interest in our future events as we move forward. Stay tuned for updates on upcoming opportunities to explore even more innovative solutions! #Curiosis #Seminar #LifeScience #CellBiology #CellResearch #Research #LiveCellImaging #Celloger #Applications

There has been an explosion in senescence research publications in the past 10 years, fueling interest in the potential of targeting #cellularsenescence as a new therapeutic approach.    As pioneers in the space, UNITY is at the forefront of developing senolytic therapies for the treatment of #DME. Learn how our senolytic candidate #UBX1325 works to target endothelial senescent cells in the retina.

IXICO lands £500k phase II Huntington's contract @IXICOnews #AIM #OTC #IXI #PHYOF. IXICO PLC (AIM:IXI, OTC:PHYOF), a neuroscience imaging company, has secured a new contract with a US-based client for a phase II clinical trial in Huntington's Disease. The agreement, valued at over £500,000, will span around two-and-a-half years. CEO Bram Goorden said: "This contract further demonstrates IXICO's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors. "Through this work we are proud to continue our support of the Huntington's Disease community, in collaboration with our sponsor, working towards a... http://ow.ly/zZEl105Rbyy

Does prediction of cognitive scores in AD trials require modeling the complexity of brain networks? Can we choose another option and use simpler QSP model, filling the gaps with the help of animal data? In our collaborative work with #GSK, we combined several pathologic mechanisms of #AD in a #QSP model to embrace different types of AD biomarkers. Despite its conciseness, the model enables description of full clinical dataset: PET(Aβ)/MRI(volume)/CSF(Aβ/tau) data, and finally, electrophysiology. Please visit our poster W-061 at #ACoP to see how this approach can be applied to prediction of therapy effect on #cognitive scores.

Neuroscience is at the precipice of massive breakthroughs, including tremendous scientific, clinical, and commercial momentum, explains Parexel. Dig into the recent report on accelerating new frontiers in neuroscience while mitigating risk. https://bit.ly/3ZpTpnF

NEW ioCells ALERT! We are proud to announce the Early Access Launch of ioAstrocytes for scientists in CNS biology and drug discovery. ioAstrocytes are functional human iPSC-derived astrocytes, deterministically programmed using opti-ox technology that convert consistently into defined astrocytes within days. ioAstrocytes offer a solution to researchers who are searching for easy-to-use, highly characterised human cells that are designed for co-culture and effectively recapitulate astrocyte functions within CNS models in vitro. Benchtop benefits - Co-culture ready: Support functional neuronal networks within co-culture settings, enabling in-vitro modelling of complex CNS biology. - Functional: Display key phagocytic and cytokine secretion functions as well as a demonstrable influence on neuronal network activity. - Consistent: Reproducible results from every vial with lot-to-lot consistency of highly characterised & defined human iPSC-derived cells. Discover ioAstrocytes: https://hubs.ly/Q02CPYcP0 #research #DrugDiscovery #astrocytes #coculture #optiox #ioCells

At the Advancing Precision Medicine Conference (APM) in Philadelphia, Mark Garner, Director of the Translational Research Segment at Agilent Technologies, participated in a discussion panel alongside Dr. Roddy O'Conner and Dr. Saba Ghassemi from the University of Pennsylvania School of Medicine. Mark highlighted the portfolio of cell analysis solutions that provide researchers with relevant tools to measure living cells, dynamically track them, and model their microenvironments. These next-generation therapies enable the assessment of real-time cell function, phenotype, and fate, ultimately allowing translational researchers and developers to achieve the necessary level of therapeutic potency and safety. Learn more on the Agilent Newsroom: https://bit.ly/41cP4FJ #PrecisionMedicine #CellTherapy #CART

Dr. Pierre Mattar of the Ottawa Hospital Research Institute discusses why winning an FBC research grant award is so important to him and his team. Learn more about his research: https://bit.ly/48FcIw7 "This award is tremendously important for our research program. It will allow us to continue to investigate how different cell types in the retina contribute to inflammatory processes associated with retinal degeneration, and to determine whether these cells can be harnessed in order to develop new therapeutic strategies."